Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2934 Versus Investigator-Selected Regimens in Relapsed/Refractory Multiple Myeloma
NCT07569757Phase 3Not yet recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jun 2026
- Primary completion
- Dec 2028
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of TQB2934 in multiple myeloma (MM), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
TQB2934
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07569757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07569757.